ClinicalTrials.gg
RecruitingNCT05136807Updated Oct 6, 2026

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

An observational study in Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jun 2016; still recruiting 10 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Monoclonal Gammopathy of Undetermined Significance · United States.

Planned enrollment
8th of 20
400 · median 217
Started
2016
the only one that year
Observational
20 of 76
10 open now
Primary completion
2027-02
later than 4 of 17 live
Registered
65th of 76
by date
Lead sponsor
3 of 76
M.D. Anderson Cancer Center

Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2016, is one of 20 observational ones, reaches primary completion later than 4 of the 17 other live ones, and was the 65th registered.

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Open to participants now

15 of the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Monoclonal Gammopathy of Undetermined Significance studies recruiting now, 18 (90%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, or all of them as a file.
02

Study summary

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.

Read the detailed description

PRIMARY OBJECTIVE:

I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM already participating in clinical trials at MD Anderson Cancer Center.

SECONDARY OBJECTIVE:

I. Identify the most common symptoms/patients concerns to evaluate future interventions for treatment/prevention in this population.

OUTLINE:

Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.

03

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering Plasma Cell Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with monoclonal gammopathy of unknown significance or smoldering multiple myeloma at MD Anderson Cancer Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with either monoclonal gammopathy of unknown significance age >= 18 years old.

    • Both criteria must be met:

      • Serum monoclonal protein \< 3 g/dL or urinary monoclonal protein \< 500 mg per 24 hours and clonal bone marrow plasma cells \< 10%
      • Absence of myeloma defining events or amyloidosis
  • OR Patients with smoldering multiple myeloma age >= 18 years old.

    • Both criteria must be met:

      • Serum monoclonal protein >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60%
      • Absence of myeloma defining events or amyloidosis
  • Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer Center, including protocols PA15-0575 (NCT02726750) (Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies); 2015-0148 (Phase II single arm trial of Isatuximab in patients with intermediate and high risk smoldering multiple myeloma); and 2015-0371 (NCT02603887) (Pilot single arm, single center, open label trial of Pembrolizumab in patients with intermediate and high risk smoldering multiple myeloma) and any future clinical trials for MGUS and/or SMM that open at MD Anderson Cancer Center.
  • Only patients who are English or Spanish speaking are eligible.

Exclusion criteria

Exclusion Criteria:

  • Evidence of myeloma defining events or biomarkers of due to underlying plasma cell proliferative disorder meeting at least one of the following

    • Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the or > 2.75 mmol/L (> 11 mg/dL)
    • Renal Insufficiency: \< 40 ml/min or serum creatinine > 2 mg/dL
    • Anemia: value \< 10 g/dL or 2 g/dL \< normal reference
    • Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT).
    • Clonal bone marrow plasma cell percentage >= 60%
    • Involved: uninvolved serum free light chain ratio >= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom [UK])
    • >1 focal lesions on magnetic resonance imaging (MRI) studies, if the patient has an MRI done per eligibility criteria (each focal lesion must be 5 mm or more in size)
  • Plasma cell leukemia.
  • Presence of cognitive impairment or delirium as determined by the primary clinician.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)

Groups and cohorts

  • Observational (quality of life questionnaire)

    Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.

    Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • OtherQuality-of-Life Assessment

    Complete questionnaires

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Complete questionnaires

06

What researchers measure

Primary outcomes

  1. Quality of life questionnaires

    Patients complete quality of life questionnaires over 10-15 minutes at baseline. Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time

    Time frame: Up to 3 years

  2. Quality of life questionnaires

    Patients complete quality of life questionnaires every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years. Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2016 (actual). Primary completion is estimated for Feb 2027, 127 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Nov 29, 2021
StartActual
Jun 7, 2016
Primary completionEst.
Feb 2, 2027
CompletionEst.
Feb 2, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05136807
Responsible party
Sponsor
First posted
Nov 29, 2021
Start date
Jun 7, 2016
Primary completion
Feb 2, 2027 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Melody Becnel, MD
Contact
mrbecnel@mdanderson.org
832-206-9804
Melody E Becnel
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion